Philip J. Larsen

Philip J. Larsen

R&D Diabetes, Sanofi Aventis Deutschland GmbH, Industriepark Höchst
Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.

Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 27, 2021

Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography.

Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography.

Journal: Diabetes

Published: October 28, 2020

The Novel Phosphate and Bile Acid Sequestrant Polymer SAR442357 Delays Disease Progression in a Rat Model of Diabetic Nephropathy.

The Novel Phosphate and Bile Acid Sequestrant Polymer SAR442357 Delays Disease Progression in a Rat Model of Diabetic Nephropathy.

Journal: The Journal of pharmacology and experimental therapeutics

Published: August 14, 2020

Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.

Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 01, 2020

Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery.

Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery.

Journal: Obesity (Silver Spring, Md.)

Published: December 20, 2019

Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates.

Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates.

Journal: Scientific reports

Published: July 19, 2019

Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery.

Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery.

Journal: The Journal of clinical endocrinology and metabolism

Published: January 09, 2019

Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.

Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.

Journal: BMC medical genomics

Published: December 13, 2018

First-in-class positron emission tomography tracer for the glucagon receptor.

First-in-class positron emission tomography tracer for the glucagon receptor.

Journal: EJNMMI research

Published: October 12, 2018

The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.

The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.

Journal: Molecular metabolism

Published: August 10, 2018

Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.

Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.

Journal: Endocrinology

Published: April 26, 2018

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.

Journal: Diabetes, obesity & metabolism

Published: February 07, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026